

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Yuko NAKAMURA *et al.*

Serial No.: 09/807,933

Based on PCT/JP99/05884

Filed: April 20, 2001

For: ENDOGLUCANASES AND CELLULASE
PREPARATIONS CONTAINING THE SAME

ATTENTION: BOX PCT

BOX MISSING PARTS

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231

April 18, 2002

Dear Sir:

In response to the Notification of Defective Response mailed March 18, 2002, applicant is submitting herewith a Third Transmittal of Sequence Listing, together with a copy of the above-mentioned Notification.

The Notification set forth a response due date of one month from the mailing date thereof. Accordingly, this response is due on or before April 18, 2002.

The Third Transmittal of Sequence Listing submitted herewith includes:
(1) a substitute paper copy of a Sequence Listing for the above-identified application that has been prepared in accordance with the sequence rules under 37 C.F.R. § 1.821 to 1.825, (2) a computer readable form of the

Sequence Listing as required in 37 C.F.R. § 1.821(e), and (3) a statement that paper copy and computer readable form of the Sequence Listing are the same and include no new matter, as required in said Notifications. Accordingly, it is respectfully requested that this application be forwarded to the examination area of the Patent Office for examination on the merits.

The Third Transmittal of Sequence Listing attached hereto corrects the missing information set forth in the Raw Sequence Listing Error Summary attached to the aforesaid Notification. Namely, in SEQ ID NO: 13, the source of the genetic material of the artificial sequence is now forth in <223> section. In addition, for SEQ ID NOS: 17-21, 25, 29-30 43 and 44, an explanation is now included in the sections <220> to <223> corresponding to the presence of n or Xaa in these SEQ ID NOS.

The foregoing is believed to be complete and proper response to the Notification of Defective Response mailed March 18, 2002. In the event there any questions concerning this response or the copies of the sequence listing attached hereto, it is respectfully requested that the undersigned be telephoned at the below listed number to resolve any outstanding issues.

In the event this paper is not timely filed, applicant hereby petitions for an appropriate extension of time. The fee therefor, as well as any other fees which become due, may be charged to our Deposit Account No. 22-0256.

Respectfully submitted,
VARNDELL & VARNDELL, PLLC
(Formerly Varndell Legal Group)



R. Eugene Varndell, Jr.
Attorney for Applicants
Registration No. 29,728

Atty. Case No. VX012273 PCT
106-A S. Columbus St.
Alexandria, VA 22314
(703) 683-9730

\\V:\VDOCS\W_DOCS\APR02\F080-2273 PCT RMP.DOC

Rec'd PCT/PTO 18 APR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Yuko NAKAMURA *et al.*

Serial No.: 09/807,933 (Based on PCT/JP99/05884)

Filed: April 20, 2001

For: ENDOGLUCANASES AND CELLULASE
PREPARATIONS CONTAINING THE SAME

THIRD TRANSMITTAL OF SEQUENCE LISTING

Honorable Commissioner
of Patents and Trademarks
Washington, D.C. 20231


April 18, 2002

Dear Sir:

Please find attached hereto a paper copy of a Sequence Listing for the above-identified application that has been prepared in accordance with the sequence rules under 37 C.F.R. § 1.821 to 1.825. Also attached hereto is an envelope containing a copy of the Sequence Listing in computer readable form as required in 37 C.F.R. § 1.821(e). The contents of the attached paper copy and computer readable form of the Sequence Listing are the same and include no new matter.

In the event any additional fees are due, please charge our Deposit Account No. 22-0256.

Respectfully submitted,
VARNDELL & VARNDELL, PLLC
(formerly Varndell Legal Group)


R/ Eugene Varndell, Jr.
Registration No. 29,728

Atty. Case No. VX012273 PCT
106-A South Columbus Street
Alexandria, Virginia 22314
(703) 683-9730

V:\VDOCS\W_DOCS\APR02\P080-2273 PCT 2SL.DOC